Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Oropharyngeal Cancer

Oropharyngeal Cancer ORIGINAL ARTICLE A Case for Single Modality Treatment With Transoral Laser Microsurgery David G. Grant, MD; Michael L. Hinni, MD; John R. Salassa, MD; William C. Perry, PA-C; Richard E. Hayden, MD; John D. Casler, MD Objective: To demonstrate the role of transoral laser mi- Results: Over the mean follow-up period of 44 crosurgery(TLM)inthetreatmentoforopharyngealcancer. months, 66 of 69 patients had no disease recurrence at the primary site. The 5-year local control estimate was Design: A 2-center retrospective case series analysis. 94%. The mean duration of hospitalization was 3 days. There were no major complications relating to TLM. Setting: Two tertiary care medical centers. No patient required a permanent feeding or tracheos- tomy tube. For stage I, II, and III disease, the 5-year Patients: The study population comprised 69 patients Kaplan-Meier estimates of locoregional control were with previously untreated select T1 to T3, N0 to N2 squa- 90%, 73%, and 70%, respectively. The 5-year overall mous cell carcinoma of the oropharynx, of whom 44 survival estimate was 86%. (74%) had no indication for adjuvant RT and 25 (36%) had an indication for adjuvant RT to the neck alone but Conclusions: Transoral laser microsurgery alone with declined radiotherapy. The primary tumor http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Otolaryngology - Head & Neck Surgery American Medical Association

Loading next page...
 
/lp/american-medical-association/oropharyngeal-cancer-A5Eox4OznR

References (9)

Publisher
American Medical Association
Copyright
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6181
eISSN
2168-619X
DOI
10.1001/archoto.2009.185
pmid
20026820
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE A Case for Single Modality Treatment With Transoral Laser Microsurgery David G. Grant, MD; Michael L. Hinni, MD; John R. Salassa, MD; William C. Perry, PA-C; Richard E. Hayden, MD; John D. Casler, MD Objective: To demonstrate the role of transoral laser mi- Results: Over the mean follow-up period of 44 crosurgery(TLM)inthetreatmentoforopharyngealcancer. months, 66 of 69 patients had no disease recurrence at the primary site. The 5-year local control estimate was Design: A 2-center retrospective case series analysis. 94%. The mean duration of hospitalization was 3 days. There were no major complications relating to TLM. Setting: Two tertiary care medical centers. No patient required a permanent feeding or tracheos- tomy tube. For stage I, II, and III disease, the 5-year Patients: The study population comprised 69 patients Kaplan-Meier estimates of locoregional control were with previously untreated select T1 to T3, N0 to N2 squa- 90%, 73%, and 70%, respectively. The 5-year overall mous cell carcinoma of the oropharynx, of whom 44 survival estimate was 86%. (74%) had no indication for adjuvant RT and 25 (36%) had an indication for adjuvant RT to the neck alone but Conclusions: Transoral laser microsurgery alone with declined radiotherapy. The primary tumor

Journal

JAMA Otolaryngology - Head & Neck SurgeryAmerican Medical Association

Published: Dec 1, 2009

There are no references for this article.